Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
2008

Dasatinib's Effects on Melanoma Cells

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): Eustace Alex J, Crown John, Clynes Martin, O'Donovan Norma

Primary Institution: National Institute for Cellular Biotechnology, Dublin City University

Hypothesis

Can dasatinib improve treatment outcomes in melanoma cell lines?

Conclusion

Dasatinib has anti-proliferative and anti-invasive effects in melanoma cells and may enhance the efficacy of chemotherapy.

Supporting Evidence

  • Dasatinib inhibited growth in three of the five melanoma cell lines tested.
  • Combination of dasatinib with temozolomide showed greater efficacy than either drug alone.
  • Dasatinib induced cell cycle arrest and apoptosis in sensitive melanoma cells.
  • Dasatinib significantly inhibited cell migration and invasion.

Takeaway

Dasatinib is a medicine that helps stop melanoma cells from growing and spreading, especially when used with other cancer drugs.

Methodology

The study examined dasatinib's effects on melanoma cell lines through various assays including proliferation, apoptosis, and migration.

Limitations

The study is limited to in vitro findings and may not fully represent in vivo responses.

Statistical Information

P-Value

0.038, 0.024

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-5876-6-53

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication